Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Predictive factors for disease progression in patients with early-onset Alzheimer's disease.

Yoon B, Shim YS, Park HK, Park SA, Choi SH, Yang DW.

J Alzheimers Dis. 2016;49(1):85-91. doi: 10.3233/JAD-150462.

PMID:
26444786
2.

Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.

Wattmo C, Wallin ÅK.

Alzheimers Res Ther. 2017 Aug 31;9(1):70. doi: 10.1186/s13195-017-0294-2.

3.

Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.

Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, Macavoy M, Gelernter J, van Dyck C.

Dement Geriatr Cogn Disord. 2006;22(1):73-82. Epub 2006 May 12.

4.

Apolipoprotein E epsilon4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients.

Marra C, Bizzarro A, Daniele A, De Luca L, Ferraccioli M, Valenza A, Brahe C, Tiziano FD, Gainotti G, Masullo C.

Dement Geriatr Cogn Disord. 2004;18(2):125-31. Epub 2004 Jun 18.

PMID:
15211066
5.

Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.

Yang YH, Wu MN, Chou PS, Su HC, Lin SH, Sung PS.

Curr Alzheimer Res. 2018 Mar 14;15(5):474-481. doi: 10.2174/1567205014666171010112518.

PMID:
29032750
6.

Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease.

van Duijn CM, de Knijff P, Cruts M, Wehnert A, Havekes LM, Hofman A, Van Broeckhoven C.

Nat Genet. 1994 May;7(1):74-8.

PMID:
8075646
7.

Cognitive profiles and neuropsychiatric symptoms in Korean early-onset Alzheimer's disease patients: a CREDOS study.

Park HK, Choi SH, Park SA, Kim HJ, Lee Y, Han SH, Kim EJ, Kim BC, Han HJ, Moon SY, Yang DW, Park KW, Park KH, Yoon B, Seo SW, Na DL, Na HR, Lee JH.

J Alzheimers Dis. 2015;44(2):661-73. doi: 10.3233/JAD-141011.

PMID:
25322926
8.

Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset.

van der Vlies AE, Koedam EL, Pijnenburg YA, Twisk JW, Scheltens P, van der Flier WM.

Psychol Med. 2009 Nov;39(11):1907-11. doi: 10.1017/S0033291709005492. Epub 2009 Apr 1.

PMID:
19335933
9.

No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease.

Murphy GM Jr, Taylor J, Kraemer HC, Yesavage J, Tinklenberg JR.

Am J Psychiatry. 1997 May;154(5):603-8.

PMID:
9137113
10.

The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival.

van Duijn CM, de Knijff P, Wehnert A, De Voecht J, Bronzova JB, Havekes LM, Hofman A, Van Broeckhoven C.

Ann Neurol. 1995 May;37(5):605-10.

PMID:
7755355
11.

Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.

Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS.

Arch Neurol. 2005 Mar;62(3):454-9.

PMID:
15767511
12.

Apolipoprotein E genotype and lifetime cognitive decline.

Kozauer NA, Mielke MM, Chan GK, Rebok GW, Lyketsos CG.

Int Psychogeriatr. 2008 Feb;20(1):109-23. Epub 2007 Aug 22.

PMID:
17711604
13.

Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease.

Brickell KL, Steinbart EJ, Rumbaugh M, Payami H, Schellenberg GD, Van Deerlin V, Yuan W, Bird TD.

Arch Neurol. 2006 Sep;63(9):1307-11.

PMID:
16966510
14.

Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains.

Smits LL, Pijnenburg YA, van der Vlies AE, Koedam EL, Bouwman FH, Reuling IE, Scheltens P, van der Flier WM.

Eur Neuropsychopharmacol. 2015 Jul;25(7):1010-7. doi: 10.1016/j.euroneuro.2015.03.014. Epub 2015 Mar 30.

PMID:
25891378
15.

APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.

Martins CA, Oulhaj A, de Jager CA, Williams JH.

Neurology. 2005 Dec 27;65(12):1888-93.

PMID:
16380608
16.

Effects of APOE haplotypes and measures of cardiovascular risk over gender-dependent cognitive and functional changes in one year in Alzheimer's disease.

de Oliveira FF, Pereira FV, Pivi GAK, Smith MC, Bertolucci PHF.

Int J Neurosci. 2018 May;128(5):472-476. doi: 10.1080/00207454.2017.1396986. Epub 2017 Nov 21.

PMID:
29064737
17.

The Role of Ethnicity in Alzheimer's Disease: Findings From The C-PATH Online Data Repository.

Chen HY, Panegyres PK.

J Alzheimers Dis. 2016;51(2):515-23. doi: 10.3233/JAD-151089.

PMID:
26890783
19.

Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline.

Amieva H, Mokri H, Le Goff M, Meillon C, Jacqmin-Gadda H, Foubert-Samier A, Orgogozo JM, Stern Y, Dartigues JF.

Brain. 2014 Apr;137(Pt 4):1167-75. doi: 10.1093/brain/awu035. Epub 2014 Feb 27.

PMID:
24578544
20.

Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.

Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, Kokmen E, Waring SC, Kurland LT.

JAMA. 1995 Apr 26;273(16):1274-8. Erratum in: JAMA 1995 Aug 16;274(7):538.

PMID:
7646655

Supplemental Content

Support Center